PKM and B-cell acute lymphoblastic leukemia: Shikonin dose-dependently inhibited glucose uptake and lactate production in pre-B cell acute lymphoblastic leukemia (BCP-ALL) [60], Lewis lung carcinoma (LLC) and B16 melanoma cells and suppressed cellular aerobic glycolysis through inhibiting PKM2 by reducing PKM2 phosphorylation.